Compound
The drug is produced in the form of tablets containing 500 mg of mefenamic acid + methylcellulose, magnesium stearate, potato starch, croscarmellose sodium, octadecanoic acid.
The medicine is also sold in capsules of 250 or 500 mg of mefenamic acid + talc, lactose monohydrate, corn starch, colloidal silicon dioxide, crospovidone, sodium lauryl sulfate, crospovidone.
Another product can be purchased in the form of a powder for preparing medicines.
Pharmacodynamics and pharmacokinetics
The active ingredient of the drug is an anthranilic acid , belongs to the group of NSAIDs and antirheumatic drugs. Thanks to its chem. properties have analgesic, anti-inflammatory, antipyretic effects.
The drug is able to reduce the intensity of the body's production of specific inflammatory mediators - serotonin and prostaglandins . The drug affects both the processes occurring in the periphery and the central mechanisms of increasing pain sensitivity, reduces the activity of lysosome proteases .
Mefenamic acid stabilizes protein ultrastructures and cell membranes, relieves swelling and reduces capillary permeability.
The antipyretic effect of the drug is due to the ability of the acid to influence the thermoregulation center in the brain and reduce the synthesis of inflammatory mediators.
The drug also has a moderate antiviral effect, stimulating the production of interferon , increasing the content of T helper cells and T lymphocytes .
3 hours after oral administration, the active substance reaches its maximum concentration in the blood . There is a linear relationship between the dose taken and the concentration of the drug in the blood plasma . The drug binds very well to proteins and undergoes metabolic in the liver.
The half-life ranges from 120 to 240 minutes. The product is excreted in feces and urine.
Pharmacological properties of the drug Mefenamic acid-Darnitsa
Mefenamic acid is an NSAID. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins, etc.) and reduce the activity of lysosomal enzymes involved in the inflammatory reaction. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, disrupts oxidative phosphorylation processes, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases cell resistance and stimulates wound healing. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center. In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine, serotonin). Unlike most other NSAIDs, Mefenamic acid-Darnitsa stimulates the formation of interferon. After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood serum is observed 2–4 hours after administration, the level in the blood is proportional to the dose taken. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day). Binds 90% to blood albumin. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. The half-life (T1/2) is 2–4 hours. It is excreted from the body unchanged and in the form of metabolites mainly through the kidneys (67% of the dose), with feces (20–25%).
Indications for use
The drug has a fairly wide range of applications:
- acute respiratory infections , viruses , influenza ;
- diseases of the musculoskeletal system , rheumatism , rheumatoid arthritis , ankylosing spondylitis ;
- primary dysmenorrhea and dysfunctional menorrhagia ;
- pain, swelling , inflammation after operations and injuries.
Mefenamic acid also prescribed for fever and fever .
Indications for use of the drug Mefenamic acid-Darnitsa
For the purpose of prevention and treatment of influenza and acute respiratory viral infections; inflammatory diseases of the musculoskeletal system: rheumatoid, gouty arthritis, rheumatism, ankylosing spondylitis (ankylosing spondylitis). Pain syndrome: ossalgia, neuralgia, myalgia, arthralgia, radiculitis, headache, pain during menstrual syndrome, childbirth (as an analgesic and tocolytic agent); in orthopedic surgery; for oncological diseases; for algodismenorrhea (can be used as a drug of choice for the treatment of moderate pain if it is necessary to use NSAIDs for more than 1 week). For local use: periodontitis (dystrophic-inflammatory forms), erosive and ulcerative lesions of the oral mucosa. Menorrhagia (associated with adenomyomas, the presence of intrauterine contraceptives, etc.).
Contraindications
The product is contraindicated:
- if you are allergic to its components;
- if after taking Aspirin or other NSAIDs the patient develops Quincke's edema , runny nose , bronchospasm , urticaria or bronchial asthma ;
- combine with specific COX-2 inhibitors ;
- with a stomach or duodenal ulcer , including a history of it;
- pregnant and lactating women;
- for inflammatory bowel diseases, diseases of the hematopoietic organs;
- children under 5 years old;
- if the patient suffers from severe heart failure, liver or kidney disease;
- with perforation or gastrointestinal bleeding.
The medicine is prescribed with caution to patients with epilepsy , arterial hypertension , coronary heart disease , systemic lupus erythematosus , ulcerative colitis and Crohn's disease (with a history).
Elderly people are at risk; their likelihood of developing side effects increases significantly.
Special instructions for the use of the drug Mefenamic acid-Darnitsa
The drug is prescribed with caution to patients with a history of allergic reactions to acetylsalicylic acid and other NSAIDs; Prescribe with caution to patients with a history of peptic ulcer of the stomach or duodenum. Use during pregnancy or breastfeeding. The drug is contraindicated during pregnancy. If it is necessary to use the drug during breastfeeding, breastfeeding should be discontinued. Ability to drive vehicles and operate other machinery . The drug can affect the speed of reactions when driving vehicles and when working with mechanisms that require increased attention. Children. The drug is contraindicated in children under 5 years of age.
Side effects
Mefenamic acid may cause:
- drowsiness , weakness, irritability, headaches , convulsions , blurred vision;
- pain in the abdomen or stomach, nausea, increased gas formation , vomiting;
- increased levels enzymes ;
- colitis , heartburn , enterocolitis , hepatitis , jaundice , pancreatitis ;
- increased blood pressure , arrhythmia ;
- gastritis , peptic ulcers without bleeding or with bleeding, constipation , diarrhea ;
- dyspnea , bronchospasm ;
- skin rashes, peripheral edema, angioedema , Stevens-Johnson syndrome , urticaria , photosensitivity , asthma , anaphylaxis ;
- rarely - congestive heart failure, peripheral , palpitations, shortness of breath ;
- capillary necrosis , polyuria ;
- aseptic meningitis glucose tolerance in patients with diabetes mellitus ;
- cystitis , dysuria , hematuria , renal failure , nephrotic syndrome ;
- aplastic anemia , decreased blood clotting, leukopenia , thrombocytopenia , agranulocytosis , pancytopenia , neutropenia ;
- hyponatremia , hyperkalemia , glomerulonephritis ;
- ringing in the ears, loss of color vision (reversible), eye irritation.
Side effects of the drug Mefenamic acid-Darnitsa
From the gastrointestinal tract: pain in the epigastric region, anorexia, heartburn, nausea, flatulence, dyspepsia, constipation, diarrhea. Increased levels of liver enzymes in blood plasma. From the respiratory system : dyspnea, bronchospasm. From the urinary system: dysuria, cystitis, renal dysfunction, albuminuria, hematuria, oliguria or polyuria. From the blood system: anemia, prolongation of bleeding time, eosinophilia, leukopenia, thrombocytopenia. From the central nervous system: drowsiness or insomnia, weakness, irritability. Skin: allergic reactions; skin rashes, itching, swelling of the face.
Instructions for Mefenamic acid (method and dosage)
The medicine is prescribed orally, after meals.
It is not advisable to split the capsules; it is better to swallow them whole.
Adults are usually prescribed 250 or 500 mg of the drug 3-4 times a day. The maximum daily dosage is 3 grams. As a rule, after achieving the desired effect, the daily dosage is reduced to one gram.
The course of treatment is determined by the attending physician. For example, for fever or for the treatment of pain, the duration of therapy is up to 7 days. The course of treatment for joint diseases ranges from 20 to 60 days.
Instructions for Mefenamic acid for children
The drug should not be prescribed to children under 5 years of age.
The dosage for children aged 5 to 12 years should not exceed one gram. As a rule, take 250 mg 3 or 4 times a day.
The course of treatment is determined by the doctor.
Mefenamine instructions for use
Instructions for medical use of the drug Mefenaminka
Composition 1 tablet contains mefenamic acid 500 mg excipients: lactose, sodium lauryl sulfate, povidone, crospovidone, corn starch, colloidal silicon dioxide, microcrystalline cellulose, talc, magnesium stearate, opadry 200 white.
Dosage form. Film-coated tablets. Basic physical and chemical properties: elongated tablets with a chamfer, with a notch, coated with a white or almost white film.
Pharmacological group. Non-steroidal anti-inflammatory drugs. ATX code M01A G01.
Pharmacological properties. Pharmacodynamics. Mefenamic acid is an NSAID. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins, etc.) and reduce the activity of lysosomal enzymes involved in the inflammatory reaction. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, disrupts oxidative phosphorylation processes, suppresses the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases cell resistance and stimulates wound healing. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center. Mefenamic acid stimulates the formation of interferon. In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine, serotonin).
Pharmacokinetics. After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood is reached 2-4 hours after administration. The blood level is proportional to the dose. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day). Binds 90% to blood albumin. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. The half-life (T1/2) is 2-4 hours. It is excreted from the body unchanged and in the form of metabolites mainly by the kidneys (67% of the dose) and with feces (20-25%).
Indications. Acute respiratory viral infections and influenza. Pain of low and medium intensity: muscle, joint, traumatic, dental, headache of various etiologies, postoperative and postpartum pain. Primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, in the absence of pathology of the pelvic organs. Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis. Contraindications. Hypersensitivity to the components of the drug. Bronchospasm, Quincke's edema, rhinitis, bronchial asthma, urticaria in history, which occurred after the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Simultaneous administration of specific COX-2 inhibitors. Peptic ulcer of the stomach and duodenum, including a history of inflammatory bowel disease, diseases of the hematopoietic organs, severe heart failure, severe liver or kidney dysfunction, gastrointestinal bleeding or perforation caused by taking non-steroidal anti-inflammatory drugs.
Interaction with other drugs and other types of interactions. Thiamine, pyridoxine hydrochloride, barbiturates, phenothiazine derivatives, narcotic analgesics, caffeine, diphenhydramine increase the analgesic effect of the drug. When used together, mefenamic acid and methotrexate increase the toxic effects of methotrexate. Antihypertensive drugs (ACE inhibitors and angiotensin II receptor antagonists): decreased antihypertensive effect. Diuretics: decreased diuretic effect. Diuretics may increase the nephrotoxicity of NSAIDs. Cardiac glycosides: NSAIDs may worsen heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides. Cyclosporines: increased risk of nephrotoxicity. Mefipristone NSAIDs should not be taken within 8-12 days of taking mefipristone; NSAIDs may reduce the effects of mefipristone. Corticosteroids: increased risk of gastrointestinal ulcers and bleeding. Antiplatelet agents and selective serotonin reuptake inhibitors: increased risk of gastrointestinal bleeding. Fluoroquinolones NSAIDs increase the risk of seizures. Aminoglycosides NSAIDs increase the risk of nephrotoxicity. Tacrolimus increases the risk of nephrotoxicity. Zidovudine NSAIDs increase the risk of hematological toxicity. The risk of joint hemorrhage and hematoma increases in HIV-positive hemophiliacs who are simultaneously treated with zidovudine. Lithium preparations reduce the excretion of lithium and increase the risk of developing lithium toxicity. Mefenamic acid increases the activity of oral anticoagulants, so their simultaneous use increases the risk of bleeding. Concomitant use with other non-steroidal anti-inflammatory drugs increases the anti-inflammatory effect and the likelihood of side effects from the gastrointestinal tract.
Features of application. Prescribe with caution to patients with acute cardiovascular failure, arterial hypertension, and coronary heart disease. Prescribe with caution to patients with epilepsy. There are no special recommendations for the use of the drug for moderate impairment of liver or kidney function. NSAIDs should be taken with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), since exacerbation of the disease is possible. Elderly patients usually have an increased risk of developing side effects from the gastrointestinal tract, so treatment should be started with a minimum dose. Patients with systemic lupus erythematosus and mixed connective tissue diseases are at increased risk of aseptic meningitis. Mefenamic acid should be discontinued at the first appearance of skin rash, mucosal damage, or any other manifestation of hypersensitivity. Taking mefenamic acid may impair female fertility and is not recommended for women who are trying to become pregnant.
Use during pregnancy or breastfeeding. The drug is used by women during pregnancy and breastfeeding.
The ability to influence the reaction rate when driving vehicles or other mechanisms. Caution should be exercised when driving vehicles or working with mechanisms that require increased attention, since sometimes the use of the drug can cause drowsiness, blurred vision, and convulsions.
Method of administration and dose. The drug should be used under the supervision of a physician, who determines the dose and duration of treatment. Use internally. The drug should be taken after meals with milk. Adults and children over 12 years old: 250-500 mg 3-4 times a day. According to indications and if well tolerated, the dose is increased to a maximum of 3000 mg; after achieving a therapeutic effect, the dose is reduced to 1000 mg / day. Children aged 5 to 12 years - 250 mg 3-4 times a day. The course of treatment for joint diseases can last from 20 days to 2 months or more. When treating pain syndrome, the course of treatment lasts up to 7 days.
Children. The drug is contraindicated in children under 5 years of age. Overdose. Symptoms: pain in the epigastric region, nausea, vomiting, drowsiness. In severe cases - gastrointestinal bleeding, respiratory depression, arterial hypertension, twitching of individual muscle groups, coma. Treatment. There is no specific antidote. Gastric lavage with a suspension of activated carbon. Alkalinization of urine, forced diuresis. Symptomatic therapy. Hemosorption and hemodialysis are ineffective due to the strong binding of mefenamic acid to blood proteins. Adverse reactions. From the digestive tract: pain in the epigastric region, anorexia, heartburn, nausea, flatulence, vomiting, enterocolitis, colitis, steatorrhea, cholestatic jaundice, hepatitis, pancreatitis, hepatorenal syndrome, hemorrhagic gastritis, ulcer, with or without bleeding. Gastrointestinal bleeding, dyspepsia, constipation, diarrhea. Increased levels of liver enzymes in blood plasma. From the cardiovascular system: arterial hypertension, arrhythmia, rarely - congestive heart failure, peripheral edema, fainting, arterial hypotension, palpitations, shortness of breath. From the respiratory system: shortness of breath, bronchospasm. From the urinary system: dysuria, cystitis. Impaired renal function, albuminuria, hematuria, oliguria or polyuria, renal failure, including papillary necrosis, acute interstitial nephritis, nephrotic syndrome, allergic glomerulonephritis, hyponatremia, hyperkalemia. Blood disorders: aplastic anemia, autoimmune hemolytic anemia, increased bleeding time, eosinophilia, leukopenia, thrombocytopenia, decreased hematocrit, thrombocytopenic purpura, agranulocytosis, neutropenia, pancytopenia, bone marrow hypoplasia. From the nervous system: drowsiness or insomnia, weakness, irritability, agitation, headache, blurred vision, convulsions. From the senses: ringing in the ears, otalgia, visual disturbances, reverse loss of the ability to distinguish colors, eye irritation. Allergic reactions: skin rashes, skin itching, facial swelling, allergic rhinitis, angioedema, laryngeal edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, urticaria, bullous pemphigus, photosensitivity, asthma, anaphylactic shock. Other: impaired glucose tolerance in patients with diabetes mellitus, aseptic meningitis.
Best before date. 2 years.
Storage conditions. Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children. Package. 10 tablets in a blister pack; 2 contour packs per pack.
Vacation category. Over the counter.
Manufacturer. JSC "Pharmaceutical"
The location of the manufacturer and its address of place of business. Ukraine, 02093, Kiev, st. Boryspilskaya, 13.
Overdose
In case of overdose, the following are observed: abdominal pain, drowsiness , nausea, vomiting, gastrointestinal bleeding , respiratory depression, convulsions, decreased blood pressure , coma .
The medicine does not have a specific antidote . Treatment options include gastric lavage, enterosorbents , forced diuresis , and urine acidification. Hemodialysis is ineffective.
Interaction
Antihypertensive drugs and ACE inhibitors , when combined with this drug, lose their ability to lower blood pressure .
When combining the drug with Thiamine , Pyridoxine Phenothiazine derivatives , caffeine , narcotic analgesics , Diphenhydramine or barbiturates analgesic effect increases .
Fluoroquinolones increase the risk of seizures, aminoglycosides and tacrolimus - nephrotoxicity.
The medicine increases the toxicity of Methotrexate .
The combined use of the drug with cardiac glycosides can increase the degree of heart failure and increase the level of glycosides in the blood.
Diuretics and Cyclosporine increase the nephrotoxicity of mefenamic acid , and the diuretic effect of diuretics .
The interval between taking Mifepristone and Meph. acid should be at least 8-12 days.
When combining the drug with corticosteroids , selective serotonin reuptake inhibitors or antiplatelet agents, the risk of gastrointestinal bleeding and perforation .
Caution should be used when combining the medicine with lithium , zidovudine , oral anticoagulants , and other NSAIDs .
Drug interactions Mefenamic acid-Darnitsa
Opioid analgesics, antithrombotics, vitamin K antagonists, pyridoxine, thiamine, phenothiazine derivatives enhance the effect of mefenamic acid. When mefenamic acid and methotrexate are used together, the toxic effects of the latter are enhanced. When used together with warfarin, the risk of gastrointestinal bleeding increases. When mefenamic acid is used concomitantly with antacids, the maximum plasma concentration of mefenamic acid increases and the AUC increases.
special instructions
In case of skin rashes, damage to the mucous membrane or other manifestations hypersensitivity reactions , discontinue use and consult a doctor.
Taking the drug can cause fertility in women, so it should not be prescribed to women who are trying to conceive a child.
While taking the medicine, it is best to refrain from driving or operating machinery.
In order to reduce the likelihood of developing side effects from the gastrointestinal tract, it is recommended to take tablets or capsules with milk.
Reviews about Mefenamic acid
There are good reviews about the medicine on the Internet. It quickly and permanently brings down the temperature, does not cause adverse reactions, and has antiviral activity. Many are satisfied with the low cost of the drug.
Reviews about the medicine:
“My child is often sick. Mefenamic acid is the only thing that helps us. I give it probably from the age of 4, now the child is 8 years old”;
“I always have a place in my medicine cabinet for the anti-inflammatory drug Mefenamic acid. This medicine often helps out when there is a high fever that needs to be brought down quickly, and it helps with the first symptoms of a cold or flu. It is easily tolerated and does not cause discomfort during use”;
“My oldest boy is 10 years old, we have been saving him since he was 5. The tablets reduce the temperature within 1 hour. I am glad that such a drug exists; not a single suppository or tablet helped us, only Mefenamic acid saved us. Now I always keep it in stock at home.”
Mefenamic acid price
The price of tablets with mefenamic acid is approximately 50 UAH for 20 pieces, with a dosage of 500 mg. The cost of capsules is 60 UAH for the same amount of medicine.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
LuxPharma* special offer
- Mefenamic acid (Mefenaminka) tab.
500 mg N20 RUB 1,380 order
show more
Pharmacy24
- Mefenamic acid-Darnitsa 500 mg N20 tablets PrAT" Pharmaceutical company "Darnitsa", Ukraine
46 UAH. order - Mefenamic acid 250 mg N20 capsules Flamingo Pharmaceuticals Ltd, India
40 UAH order
Mephenamine Tablets
CONFIRMED
Order of the Ministry of Health of Ukraine
13.01.2020 № 48
Registration update
№ UA/14487/01/01
INSTRUCTIONS
for medical purposes
Mefenamina®
( Mefenamyn to a )
Stock:
active speech: mefenamic acid;
1 tablet of mefenamic acid 500 mg;
additional ingredients: lactose monohydrate, sodium lauryl sulfate, povidone, crospovidone, pregelatinized starch, anhydrous silica, microcrystalline cellulose, talc, magnesium stearate, opadry 200 white.
Medicine form. Tablets, sealed with film.
Main physical and chemical properties: tablets of subdued shape with a biconvex surface, with a score, closed with a white or slightly white color.
Pharmacotherapeutic group. Non-steroidal anti-inflammatory and anti-rheumatic agents. Fenamati. ATX code M01A G01.
Pharmacological power.
Pharmacodynamics.
Mefenamic acid is a non-steroidal anti-inflammatory drug. The mechanism of anti-inflammatory activity suppresses the synthesis of inflammation mediators (prostaglandins, serotonin, kinins, etc.), reduces the activity of lysosomal enzymes, which take part in inflammation reactions. Mefenamic acid stabilizes protein ultrastructures and cell membranes, changes the permeability of blood vessels, disrupts the processes of oxide phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of fire, etc. Promotes cell resistance and stimulates healing of wounds. The fever-reducing power is associated with the creation of gallbladder synthesis of prostaglandins and flows into the center of thermoregulation.
Mefenamic acid stimulates the release of interferon.
In the mechanism of analgesic action, in addition to the influx on the central mechanisms of pain sensitivity, the main role is played by the local influx at the site of inflammation and the creation of galvanization of algogens (kinins, g istamine, serotonin).
Pharmacokinetics.
After stagnation, mefenamic acid will continue to soak up the herbal tract. Peak blood concentrations occur 2–4 years after administration. Rhubarb in the blood is proportional to the dose. The same concentration (20 mcg/ml) is calculated per 2 doses of infusion (1 g 4 times per dose). Associated 90% with blood albumins. The liver produces metabolites through oxidation, hydrolysis, and glucuronidation. The recovery period (T1/2) is 2–4 years. It is important to excrete from the body unchanged and in the form of metabolites in alcohol (67% of the dose), in feces (20–25%).
Clinical characteristics.
Showing.
Acute respiratory viral infections and influenza.
Pain of low and moderate intensity: fleshy, sore throat, traumatic, dental, headache of various etiologies, post-operative and post-acute pain.
Primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, due to pathology of the pelvic organs.
Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis.
Contraindicated.
Sensitivity to the components of the medicinal care has been increased. Bronchospasm, angioedema, rhinitis of the allergic type to mefenamic acid, bronchial asthma or a history of urticaria, which occurred after exposure to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). One-hour administration of specific COX-2 inhibitors. Virazkova disease of the vulva and duodenum, including in the anamnesis, inflammation of the intestines, disease of the hematopoietic organs, severe heart failure, severe damage to the function of the liver or niroki, scutulo-intestinal bleeding or perforation ation caused by the use of NPZD. Pain relief after coronary artery bypass surgery.
Interactions with other medicinal drugs and other types of interactions.
Concomitant administration of mefenamic acid with other medications that bind to plasma proteins may require dosage adjustments.
Thiamine, pyridoxine hydrochloride, barbiturates, phenothiazine derivatives, narcotic analgesics, caffeine, diphenhydramine: enhance the analgesic effect of the drug.
If mefenamic acid and methotrexate are ingested too much, the toxic effects of methotrexate may increase.
Antihypertensive agents (ACE inhibitors and angiotensin II receptor antagonism): decreased antihypertensive effect, increasing the risk of nicotine deficiency, especially in patients with advanced age. Patients are responsible for living as long as possible. It is also necessary to evaluate the function of nirok on the cob of treatment and during concomitant therapy.
Acetylsalicylic acid (aspirin): experimental evidence suggests that, when concomitantly administered, mefenamic acid may interfere with the antiplatelet effect of low doses of aspirin and may therefore reduce the effectiveness prophylactic treatment of cardiovascular diseases with aspirin. However, due to the limited number of experimental data and the lack of significance of extrapolating ex vivo data to the clinical situation, it is not possible to obtain clear results regarding the consistent infusion of mefenamic acid during regular infusion.
Diuretics: reduction of sechoginic effect. Diuretics may increase the nephrotoxicity of NSAIDs.
Cardiac glycosides: NSAIDs may aggravate cardiac failure, alter glomerular filtration rate, and increase plasma levels of cardiac glycosides.
Cyclosporine: increased risk of nephrotoxicity.
Mifepristone: NSAIDs should not be taken for 8-12 days after taking mifepristone - NSAIDs may reduce the effect of mifepristone.
Corticosteroids: stimulating the development of scilico-intestinal tumors and bleeding.
Antiplatelet agents and selective inhibitors of renal serotonin accumulation: promoting the risk of sulcus-intestinal bleeding.
Fluoroquinolones: NPZP pushes the risk development by the court.
Aminoglycosides: NSAIDs promote the risk of developing nephrotoxic effects.
Tacrolimus: may increase the risk of developing a nephrotoxic effect.
Zidovudine: NSAIDs increase the risk of hematological toxicity. There is an increasing risk of hemorrhage in the lump and hematoma in IL-positive patients with hemophilia, which is immediately reversed by treatment with zidovudine.
Lithium preparations: reducing the excretion of lithium and reducing the risk of developing toxicity. Patients taking mefenamic acid and lithium preparations must be monitored closely by a physician for signs of toxicity.
Mefenamic acid promotes the activity of oral anticoagulants, and when they are stagnated overnight, the risk of bleeding increases. Acute administration of mefenamic acid to oral anticoagulants will require careful monitoring of the prothrombin hour. NSAIDs containing warfarin or heparin should be administered with special care and under medical supervision.
Oral hypoglycemic effects: inhibition of the metabolism of sulfonyl compounds, prolongation of the recovery period and increased risk of hypoglycemia.
Simultaneous treatment with other NSAIDs promotes the protivo-palatal effect and the likelihood of side effects on the side of the intestinal tract.
Features of stagnation.
Adverse reactions of mefenamic acid may be minimized when the lowest effective dose is administered for a short period of time.
When treated with mefenamic acid, patients should be monitored closely until liver dysfunction, viscera, blood dyscrasia, or diarrhea occur. If the development of any of these pathological conditions or symptoms is detected, it is imperative to take treatment.
Trying the drug for headache relief can lead to further relief. In this case, you should take medical treatment and consult a doctor.
Mefenamic acid should be administered with caution to patients suffering from vomiting, diarrhea or increased diuresis, patients with nitric deficiency, especially patients of the summer age.
Summer age patients may have an increased incidence of adverse reactions associated with NSAIDs, especially bowel bleeding and perforation, which can lead to death. The drug should remain stable at the lowest effective dose for a short period of time. During therapy with NSAIDs, it is necessary to control the state of the scutulo-intestinal tract to prevent possible damage, especially the occurrence of scutulo-intestinal bleeding. Use caution when administering mefenamic acid to patients who have suffered from fever or illness. Episodes of non-oliguric nitric deficiency and proctocolitis have been reported, which were mainly recorded in patients with summer age, which was not due to the stagnation of mefenamic acid after the onset of diarrhea.
Taking mefenamic acid can lead to disorders in the side of the intestinal tract (for example, diarrhea). The stench can arise both immediately after the medicinal product has been stagnant, and after taking it for a long time. If such symptoms occur, it is necessary to initiate treatment with a doctor.
Medical treatment should be used with caution to treat patients with acute cardiovascular insufficiency, arterial hypertension, or ischemic heart disease.
The doctor's appointment with caution is to diagnose patients with epilepsy.
Use caution when administering mefenamic acid to patients with bronchial asthma (including those with a history of asthma), as it has been reported that NSAIDs in such patients accelerate the development of bronchospasm.
Stagnation of NSAIDs can lead to a dose-dependent decrease in the synthesis of prostaglandins and provoke the development of nicotine deficiency. The greatest risk for the development of this reaction is in patients with impaired function of the liver, liver, heart failure, patients taking diuretics, and patients of the summer age. In such patients, it is necessary to monitor the function of the neuron.
When mefenamic acid is frozen, the liver function may be severely impaired. Patients who have such disorders should take medication as soon as possible. Patients who take mefenamic acid for an extended period of time may be under the supervision of a doctor due to the possibility of impaired liver function and harm.
In case of severely impaired liver function, there are no special recommendations for stopping the medicinal procedure.
Clinical and epidemiological data suggest that the use of certain NSAIDs (especially at high doses and over three hours) may be associated with minor increases in the risk of arterial disease development thrombotic events (for example, myocardial infarction or stroke). There is insufficient data to exclude such a risk when taking mefenamic acid.
If it is necessary to instill mefenamic acid, patients with cardiovascular and cerebrovascular diseases should consult a doctor. During the hour of treatment, it is not possible to increase the recommended dose or the severity of the treatment. Patients with uncontrolled arterial hypertension, congestive heart failure, diagnosed with ischemic heart disease, diseases of the peripheral arteries and/or cerebrovascular diseases of the liver Mefenamic acid can be prescribed as a medicine only after a renal analysis of the joint cortex/rizik. For patients with a clear history of arterial hypertension and/or congestive heart failure of mild or moderate severity, it is necessary to carry out thyroid fastening and discontinue the recommendation. and the doctor, the fragments in the connection from the stagnation of the oil refinery, episodes of jamming in the middle and scratches were registered. Patients with factors at risk of cardiovascular complications (such as arterial hypertension, hyperlipidemia, cardiovascular diabetes, pallor) treated with mefenamic acid may be prescribed a medicine after renal anal Because of the associated measles/rizik.
It is recommended to administer mefenamic acid with caution to patients with intracranial hemorrhage and hemorrhagic disease through the use of an NSAID to suppress platelet function.
There is information about the types of potentially fatal intestinal hemorrhages, complications or perforations that occurred at any stage of treatment of NSAIDs, regardless of the presence of pre-chewing symptoms or severe disorders in the side. history of neo-intestinal tract. Alcohol consumption and exposure to alcohol have additional risk factors.
NPZZ should be taken with caution to patients who have a history of illness of the intestinal tract (viral colitis, Crohn's disease), and possibly acute illness. If the stagnation of mefenamic acid has led to intestinal bleeding or perforation, treatment with the drug must be discontinued.
Patients of the summer age are likely to suffer from advanced rhizics and the development of side effects on the side of the scutulo-intestinal tract, especially scutulo-intestinal bleeding and perforation, which can lead to death, which will lead to the need for treatment Or with the least amount of dosing.
The risk of development of scutulo-intestinal bleeding, bleeding or perforation advances with higher doses of NSAIDs, when there is evidence of bleeding in the anamnesis, especially if there is a history of bleeding or perforation, and in the patient ntiv summer century. Patients with a risk of development of scutulo-intestinal bleeding, such as patients with summer age, as well as patients who simultaneously take low doses of acetylsalicylic acid (aspirin) or other drugs and ways that can increase the risk for the scolio-intestinal tract, as soon as possible combination treatment with protective drugs (for example, misoprostol or proton pump inhibitors).
Patients with systemic worms and mixed tissue diseases are at increased risk of aseptic meningitis.
Mefenamic acid should be used with caution in patients at high risk of developing serious skin reactions, such as exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis. Mefenamic acid should be taken at the first appearance of skin rash, swelling of the mucous membrane, or any other manifestation of hypersensitivity.
When taking a long-term medication, it is necessary to monitor blood levels, as mefenamic acid fragments can cause pathological changes in the blood. In case of any manifestations of dyscrasia, it is necessary to initiate medicinal therapy.
Caution should be exercised in patients taking concomitant mefenamic acid in order to avoid concomitant therapy with medications that increase the risk of gastrotoxicity or bleeding, such as corticosteroids, anticoagulants (eg treasure, warfarin), selective inhibitors of serotonin secretion or antiplatelet agents.
There is evidence that medications that inhibit cyclooxygenase/prostaglandin synthesis may impair women's fertility, interfering with ovulation. This process is reversed after the administration of the bath. Taking mefenamic acid may impair female fertility and is not recommended for women at risk of pregnancy. If women suffer from symptoms of dysmenorrhea and menorrhagia and the presence of a clinical effect, it is necessary to contact a doctor.
Mefenamic acid should be administered with caution to patients who are extensive CYP2C9 metabolizers, as well as to patients who are extensive CYP2C9 metabolizers, based on their metabolism. of our CYP2C9 substrates, such patients may have abnormally high levels of mefenamic acid in blood plasma as a result of the decrease metabolic clearance.
Important information about additional speeches.
If you have a known intolerance to certain drugs, consult your doctor before taking this medication.
It is advisable to use less than 1 mmol (23 mg)/dose of sodium to avoid sodium.
Suspension during pregnancy or breastfeeding.
The medical advice should not be given to women during pregnancy or breastfeeding.
This is due to the fluidity of the reaction during treatment with vehicles or other mechanisms.
Be careful when using vehicles or robots with mechanisms that require increased attention, some of the drug may cause drowsiness, blurred vision, and judgement.
Method of congestion and dosage.
Obtain a medical test under the supervision of a doctor, which indicates the dose and severity of the treatment. Stand in the middle. Take the medicine after you go.
Adults and children over 12 years of age are prescribed 250–500 mg 3–4 times a day. If indicated and if the dose is well tolerated, increase the dose to a maximum of 3000 mg, and after achieving a therapeutic effect, reduce the dose to 1000 mg/dose.
Children aged 5 to 12 years - 250 mg 3-4 times a day.
The course of treatment for cold sores can be extended from 20 days to 2 months or more. When treating pain syndrome, the course of therapy lasts up to 7 days.
Children.
Medical advice on contraindications for children under 5 years of age.
Overdose.
Symptoms: pain in the epigastric region, nausea, vomiting, drowsiness. In severe episodes – intestinal hemorrhage, suppressed breathing, arterial hypertension, ingestion of certain groups of ulcers, coma.
Likuvannya: a specific antidote of the day. Washing the slug with a suspension of activated vugill. Subsistence of cutting, forcing diuresis. Symptomatic therapy. Hemosorption and hemodialysis are ineffective due to the binding of mefenamic acid to blood proteins.
Adverse reactions.
On the side of the organs of the eye: the destruction of the eye, the reverse waste of the property, the separation of colors, the teasing of the eyes.
On the side of the hearing and vestibular apparatus: ringing in the ears, otalgia.
On the side of the respiratory system, organs of the chest and mediastinal: dyspnea, bronchospasm.
On the side of the scoli-intestinal tract: pain in the epigastric dilation, anorexia, burning, boredom, flatulence, vomiting, enterocolitis, colitis, chronic colitis and Crohn's disease, gastritis, hepatotoxicity, steatorrhea, cholestatic diarrhea , hepatitis, pancreatitis, hepatorenal syndrome, hemorrhagic gastritis , peptic infection with or without bleeding. Saline-intestinal bleeding, perforation or gastrointestinal bleeding, sometimes with lethal hemorrhage, especially in late-life patients, dyspepsia, constipation, diarrhea.
On the side of the genitourinary system: dysuria, cystitis. Impaired nirofunction, albuminuria, hematuria, oliguria or polyuria, niro deficiency, including papillary necrosis, acute interstitial nephritis, nephrotic syndrome, allergic glomerulonephritis, hyponatremia, hyperkalemia.
On the side of the nervous system: drowsiness or insomnia, weakness, restlessness, restlessness, headache, blurred vision, seizures, neuritis of the visual nerve, paresthesia, confusion, rigidity of the urinary muscles, fever, loss of orientation tsії.
On the side of the psyche: confusion of information, depression, hallucinations.
On the side of the cardiovascular system: arterial hypertension, arrhythmia, rarely congestive heart failure, peripheral plaques, syncope, arterial hypotension, heart palpitations, dyspnea, thrombotic complications (for example, myocardial infarction or stroke).
On the side of the blood and lymphatic system: aplastic anemia, autoimmune hemolytic anemia, prolonged bleeding, eosinophilia, leukopenia, thrombocytopenia, decreased hematocrit, thrombocytopenic purpura, agranulocytosis, neutropenia Ia, pancytopenia, hypoplasia of the cerebellum.
On the side of the immune system: hypersensitivity reactions, including scalp rash, scalp itching, facial plaque, allergic rhinitis, angioneurotic plaque, laryngeal plaque, Stevens-Johnson syndrome, toxic epidermal necrolysis , erythema multiforme, kropiv'yanka, bullous pemphigus, photosensitiveness, asthma, anaphylaxis.
On the side of the skin and under the skin: purpura, skin rash, skin rash, erythema multiforme, urticaria, bullous pemphigus.
Laboratory findings: impaired glucose tolerance in patients with diabetes, a positive reaction in certain tests for the detection of mefenamic acid and its metabolites in animals. Increased level of liver enzymes in blood plasma.
Others: aseptic meningitis, fatigue, increased fatigue, fatigue, multiple organ failure, hyperthermia.
Information about suspected adverse reactions.
Reporting suspected adverse reactions after drug registration is an important procedure. This allows for monitoring of the “measles/risk” relationship for a specific patient. Healthcare professionals should report any suspected adverse reactions through the national reporting system.
Term of attribution. 3 rocks.
Save your mind.
Store in original packaging at a temperature not exceeding 25 °C.
Keep out of the reach of children.
Package.
10 tablets per contour charunkovy package; 1 or 2 contour charunkov packaging per pack.
Release category. Over the counter.
Virobnik. PrJSC "Pharmaceutical Firm "Darnitsa".
The locality of the distributor and the addresses of the locality for the promotion of its activities.
Ukraine, 02093, m. Kiev, st. Boryspilska, 13.
I'll look at the remaining date.
